Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RM-1995 Photoimmunotherapy in Advanced cuSCC or HNSCC
NCT05220748Phase 1Withdrawn
- Sponsor
- Rakuten Medical, Inc.
- Start
- Mar 2022
- Primary completion
- Jan 2023
- Modality
- Small Molecules, Antibody-Drug Conjugates (ADCs), Monoclonal Antibodies
01
Overview
Phase 1, open-label trial of RM-1995 in cutaneous squamous cell carcinoma (cSCC) and head and neck squamous cell carcinoma (HNSCC) (2 arms), sponsored by Rakuten Medical, Inc. Primary endpoints: Safety and Tolerability of RM-1995 at 24 months and Maximum Tolerated Dose or Maximum Administered Dose at 24 months. Planned start Mar 2022; status: withdrawn.
02
Drugs
RM-1995
03
Conditions
cutaneous squamous cell carcinoma (cSCC)head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on NCT05220748.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05220748.